SLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels [Yahoo! Finance]
Silence Therapeutics Plc - American Depository Share (SLN)
Company Research
Source: Yahoo! Finance
candidate, zerlasiran, to treat atherosclerotic cardiovascular disease (ASCVD) patients with high lipoprotein(a) or Lp(a), a key genetic risk factor for cardiovascular disease. The stock price drop is likely due to investors' skepticism regarding the effectiveness of the candidate compared to other treatments being developed for the same indication. The results from the phase II ALPACAR-360 study of zerlasiran for the ASCVD indication were presented at a medical conference in Chicago, IL, and simultaneously published in the Journal of the American Medical Association. Per the data readout, zerlasiran, administered at doses of 300 mg every 16 or 24 weeks or 450 mg every 24 weeks, achieved more than 80% mean time-averaged placebo-adjusted reductions in Lp(a) levels over 36 weeks, with maximum reductions surpassing 90%. At the final follow-up, 60 weeks after the initial dose, Lp(a) reductions were sustained, and the treatment remained safe with infrequent dosing. However, it was al
Show less
Read more
Impact Snapshot
Event Time:
SLN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SLN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SLN alerts
High impacting Silence Therapeutics Plc - American Depository Share news events
Weekly update
A roundup of the hottest topics
SLN
News
- New Amsterdam sees success in Phase III cardiovascular disease trial [Yahoo! Finance]Yahoo! Finance
- Silence Therapeutics plc (NASDAQ: SLN) had its "outperform" rating re-affirmed by analysts at William Blair.MarketBeat
- Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual MeetingBusiness Wire
- Silence Therapeutics plc (NASDAQ: SLN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.MarketBeat
SLN
Sec Filings
- 11/18/24 - Form 6-K
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- SLN's page on the SEC website